Raf-1 GST RBD 1-149 Citations (19)
Originally described in: Two distinct Raf domains mediate interaction with Ras.Brtva TR, Drugan JK, Ghosh S, Terrell RS, Campbell-Burk S, Bell RM, Der CJ J Biol Chem. 1995 Apr 28. 270(17):9809-12. PubMed Journal
Articles Citing Raf-1 GST RBD 1-149
| Articles |
|---|
| RasGRF2 Rac-GEF activity couples NMDA receptor calcium flux to enhanced synaptic transmission. Schwechter B, Rosenmund C, Tolias KF. Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14462-7. doi: 10.1073/pnas.1304340110. Epub 2013 Aug 12. PubMed |
| Development and application of a quantitative multiplexed small GTPase activity assay using targeted proteomics. Zhang CC, Li R, Jiang H, Lin S, Rogalski JC, Liu K, Kast J. J Proteome Res. 2015 Feb 6;14(2):967-76. doi: 10.1021/pr501010v. Epub 2015 Jan 21. PubMed |
| KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Leiser D, Medova M, Mikami K, Nisa L, Stroka D, Blaukat A, Bladt F, Aebersold DM, Zimmer Y. Mol Oncol. 2015 Apr 14. pii: S1574-7891(15)00089-7. doi: 10.1016/j.molonc.2015.04.001. PubMed |
| p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability. Fabris L, Berton S, Pellizzari I, Segatto I, D'Andrea S, Armenia J, Bomben R, Schiappacassi M, Gattei V, Philips MR, Vecchione A, Belletti B, Baldassarre G. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13916-21. doi: 10.1073/pnas.1508514112. Epub 2015 Oct 28. PubMed |
| PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis. Yang M, Lewinska M, Fan X, Zhu J, Yuan ZM. Oncogene. 2016 Oct 20;35(42):5527-5538. doi: 10.1038/onc.2016.93. Epub 2016 Apr 4. PubMed |
| Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis. Jinesh GG, Molina JR, Huang L, Laing NM, Mills GB, Bar-Eli M, Kamat AM. Cell Death Discov. 2016 Feb 1;2:16003. doi: 10.1038/cddiscovery.2016.3. eCollection 2016. PubMed |
| Secreted Glioblastoma Nanovesicles Contain Intracellular Signaling Proteins and Active Ras Incorporated in a Farnesylation-dependent Manner. Luhtala N, Aslanian A, Yates JR 3rd, Hunter T. J Biol Chem. 2017 Jan 13;292(2):611-628. doi: 10.1074/jbc.M116.747618. Epub 2016 Dec 1. PubMed |
| The extracellular matrix protein EMILIN1 silences the RAS-ERK pathway via alpha4beta1 integrin and decreases tumor cell growth. Modica TME, Maiorani O, Sartori G, Pivetta E, Doliana R, Capuano A, Colombatti A, Spessotto P. Oncotarget. 2017 Apr 18;8(16):27034-27046. doi: 10.18632/oncotarget.15067. PubMed |
| CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. Taoka R, Jinesh GG, Xue W, Safe S, Kamat AM. Apoptosis. 2017 May;22(5):719-729. doi: 10.1007/s10495-017-1359-1. PubMed |
| Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Yurugi H, Marini F, Weber C, David K, Zhao Q, Binder H, Desaubry L, Rajalingam K. Oncogene. 2017 Aug 17;36(33):4778-4789. doi: 10.1038/onc.2017.93. Epub 2017 Apr 17. PubMed |
| The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. Jinesh GG, Kamat AM. Cancer Res. 2017 Nov 15;77(22):6144-6156. doi: 10.1158/0008-5472.CAN-17-0522. Epub 2017 Aug 30. PubMed |
High-content tripartite split-GFP cell-based assays to screen for modulators of small GTPase activation.
Koraichi F, Gence R, Bouchenot C, Grosjean S, Lajoie-Mazenc I, Favre G, Cabantous S.
J Cell Sci. 2018 Jan 8;131(1). pii: jcs.210419. doi: 10.1242/jcs.210419.
PubMed
Associated Plasmids |
| Failure to detect functional transfer of active K-Ras protein from extracellular vesicles into recipient cells in culture. Luhtala N, Hunter T. PLoS One. 2018 Sep 7;13(9):e0203290. doi: 10.1371/journal.pone.0203290. eCollection 2018. PubMed |
| SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Jones GG, Del Rio IB, Sari S, Sekerim A, Young LC, Hartig N, Areso Zubiaur I, El-Bahrawy MA, Hynds RE, Lei W, Molina-Arcas M, Downward J, Rodriguez-Viciana P. Nat Commun. 2019 Jun 10;10(1):2532. doi: 10.1038/s41467-019-10367-x. PubMed |
| Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D. Johnson CW, Lin YJ, Reid D, Parker J, Pavlopoulos S, Dischinger P, Graveel C, Aguirre AJ, Steensma M, Haigis KM, Mattos C. Cell Rep. 2019 Aug 6;28(6):1538-1550.e7. doi: 10.1016/j.celrep.2019.07.026. PubMed |
| KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. Zhou ZW, Ambrogio C, Bera AK, Li Q, Li XX, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu CX, Janne PA, Westover KD. Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-20-0448. doi: 10.1158/0008-5472.CAN-20-0448. PubMed |
| Akt-mediated Ephexin1-Ras interaction promotes oncogenic Ras signaling and colorectal and lung cancer cell proliferation. Kim J, Jeon YJ, Lim SC, Ryu J, Lee JH, Chang IY, You HJ. Cell Death Dis. 2021 Oct 28;12(11):1013. doi: 10.1038/s41419-021-04332-0. PubMed |
| KLHL7 promotes hepatocellular carcinoma progression and molecular therapy resistance by degrading RASA2. Chen L, Li Y, Chen Y. iScience. 2023 May 19;26(6):106914. doi: 10.1016/j.isci.2023.106914. eCollection 2023 Jun 16. PubMed |
| GLUT3 promotes macrophage signaling and function via RAS-mediated endocytosis in atopic dermatitis and wound healing. Yu DM, Zhao J, Lee EE, Kim D, Mahapatra R, Rose EK, Zhou Z, Hosler C, El Kurdi A, Choe JY, Abel ED, Hoxhaj G, Westover KD, Cho RJ, Cheng JB, Wang RC. J Clin Invest. 2023 Nov 1;133(21):e170706. doi: 10.1172/JCI170706. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.